Additional detail is teased out, with relevance to women’s malignancies, in “The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.” Here, Reinbolt and Hays review the data on the use of PARP inhibitors in ovarian, endometrial, and cervical cancer, and discuss their vision regarding future directions for their development. The gene discussed is PARP1; the disease is cervical cancer.